All posts by medical

Anatomy of an Origin miracle: The manoeuvres behind Hunts magic moment – Sydney Morning Herald

Cherry-Evans finished with 642 kicking metres from 19 punts, on occasion even launching a long-range effort on the second tackle to turn the Blues back three around and nullify their all-important running game.

Queensland didnt mind if NSW had ball in hand as long as it was at their own end, with panicked mistakes from Jarome Luai, Stephen Crichton and Siosifa Talakai giving the Maroons the best of both worlds.

So when the Blues did finally work their way back up-field while trailing 16-12 the added defensive efforts took their toll, Queensland duly having their measure as the stakes increased by the second.

Heres how those frantic final moments and the catalyst of a miracle Origin play panned out.

74.03: After NSW finally start a set somewhere other than their own goal line, Damien Cook and James Tedesco are sniping around the ruck to have Queensland back-pedalling.

Loading

Clearys last-tackle bomb is missed by all as it comes down 12 metres from the try line, Jake Trbojevic of all people following up with a grubber. Tom Dearden covers it with no NSW chasers in pursuit.

76.04: After a grinding Queensland set the Blues are again in decent field position and load up with a right-side shift.

Theres time, space and an overlap out wide, but Isaah Yeo plays short to prop Jacob Saifiti and Dearden is able to bring him down. Clearys bomb back across field is taken by Gagai with the chasers five metres away from being able to challenge him.

77.01: With the Maroons again battling for yardage, Cherry-Evans kicks long and low for the touchline. Daniel Tupou cuts it off but is belted off his feet and into a slow play-the-ball by Tino Faasuamaleaui.

77.45: The Penrith connection swings into gear to create another overlap down the right through Cleary and Yeo. But a critical read from Corey Oates sees the veteran winger flying in on Stephen Crichton who is turned back inside toward Queenslands cover defence.

78.02: The miracle moment. Cleary takes the ball 32 metres out on the last with 10 metres between him and the defence.

NSW has five players lined up outside on the left to Queenslands four defenders because Gagai is already sat back deep in anticipation of another bomb.

Cleary goes to the line as Hunt pushes across to pressure him. Luai is on Clearys outside, Tedesco on his right, both ready to pursue the chip kick that comes once Cleary steps back sharply inside for the all-or-nothing play.

Loading

Hunt clutches the ball as it comes off Clearys right boot. Hes going for the charge-down but critically, never takes his eyes off the Steeden.

When Cleary delivers a deft rather than hefty touch, Hunt is airborne but latches on with both hands.

He lands, pivots, and takes off with only Yeo anywhere near him. Just 75 metres 80 he was already correcting observers in the sheds afterwards between him and a slice of Origin history.

See the rest here:
Anatomy of an Origin miracle: The manoeuvres behind Hunts magic moment - Sydney Morning Herald

Anatomy of Unatu standoff with government | Monitor – Monitor

When the Uganda National Teachers Union (Unatu) and other public service unions signed Collective Bargaining Agreement (CBA) with the government on June 22, 2018, the public servants under the umbrella body thought the worst was behind them.

The CBA highlighted plans for salary enhancement across all categories of civil servants for Financial Years 2018/2019 and 2019/2020.

It, however, didnt take long to run into trouble.

In 2019, Unatu leadership mobilised teachers across the country to withdraw labour over delayed salary enhancement.

Consequently, President Museveni summoned teachers representatives and persuaded them to suspend the strike.

The salary enhancement discussions were put on the back-burner when schools shut their doors to two Covid-19 variants across nearly two years. The schools finally re-opened this January when pandemic curbs were relaxed.

On May 23, Unatus standing committee sat and unanimously ratified the resolution resolved to down their tools on June 15, if there was no satisfactory feedback on the issues pertaining to teachers salary increment across the board for Financial Year 2022/2023.

Mr Filbert Baguma, Unatus secretary general, added thus: Every financial year, teachers have to remind government about the commitments earlier made. Do teachers really matter to this nation? Are the commitments made by government mere boardroom gimmicks meant to silence teachers and foil any plans for industrial action?

Mr Baguma also revealed that due to alleged constant disappointments, anxiety was mounting among teachers.

Only satisfactory feedback from the government on their demands, he added, would stop the intended industrial action in its tracks.

In its absence, as promised, nearly 120,000 Arts teachers in government-aided primary and secondary schools downed their tools on June 15.

It would straddle more than a fortnight before the Arts teachers grudgingly accepted this past week to take up the chalk.

The call for industrial action came after Science teachers under their unionthe Uganda Profession Teachers Union (UPSTU)suspended their strike indefinitely.

The strike had been declared at the start of the second term. The Science teachers relented after the government assured them that the Budget for the 2022/2023 financial year catered to their salary enhancement.

On May 23, Unatu issued a notification to government expressing intention to resume their industrial action if government insisted on implementing discriminatory salary enhancements instead of honouring commitments made in the 2018 CBA.

Mr Baguma said during the signing of the CBA, it was also agreed that negotiations for 2020/2021 and 2022/2023 aimed at removing disparities in scales would proceed as agreed.

He further noted that while some categories of civil servants in the CBAparticularly those in phase onereceived their increment in full, teachers, who were supposed to benefit from phase two, received only 25 percent of the expected increment.

The Unatu secretary general, however, hastened to add that the union leadership was still open for further negotiations.

The option of a strike was not taken off the table, although, especially if their issues were not addressed.

A week into the Arts teachers strike, Ms Ketty Lamarothe Permanent Secretary in the Ministry of Education and Sportsrevealed that Unatus concerns were being discussed, internally.

Teachers should desist from anything that disrupts teaching and learning. Schools were grossly affected by the Covid-19 lockdown, and we are now trying to accelerate learning to recover the lost time, she noted, adding, [The Arts teachers] salaries will be enhanced, but in a phased manner because government does not have enough money to pay everyone at the same time.

Ms Catherine Bitarakwate, the Public Service ministry Permanent Secretary, also reiterated Ms Lamaros appeal.

Unatu though, was unwavering in its demand that the government pay Shs4.8m to graduate secondary school Science teachers and Shs4.5m for their Arts counterparts, among other categories. It wasnt long before the First Lady Janet Museveniwho also doubles as Education and Sports ministerinvited Unatus top brass for a meeting originally scheduled for June 17 but pushed to June 18 at State House, Entebbe.

The meeting, which was held behind closed doors, was addressed by President Museveni. Mr Usher Wilson Owere, the chairman general of National Organisation of Trade Union (Notu), described the meeting as stormy. Mr Museveni is reported to have advised the Arts teachers to return to work, promising that their enhancement would be done in a phased manner.

The Unatu top brass, which is said to have taken offence with the Presidents tone, defied his directive to return to class.

Not even a June 22 letter from Ms Bitarakwate that described the current industrial action by the members of Unatu as illegal swayed the teachers. The letterwhich in no uncertain terms said the striking teachers had decided to close the schools and that no teacher has the legal right or justification to close a public school without the concurrence of the governmentwas roundly criticised by the public.

Keen to mend fences, Ms Bitarakwate and Vice President Jessica Alupo wrote to Unatu on June 27 seeking an audience.

The Unatu top brass met with Ms Alupo on June 28, but the discussions helddescribed as cordial by Mr Bagumayielded no results.

On June 30, Unatu received two letters from the government directing teachers to return to class as negotiations continue.

The letters from Public Service Minister Wilson Muruli Mukasa and Ms Bitarakwate repeated explanations that scientists were cleared for salary enhancements because they are needed in crucial areas of the economy such as agriculture, industry, and ICT.

The letters precipitated a July 3 meeting involving members of Unatus national executive council.

While Unatu resolved to continue with the strike, there was a change in tune when the teachers met President Museveni on July 3. The teachers resolved to return to class effective July 6, with Mr Museveni later tweeting please dont divert us from our journey of attracting and retaining scientists by paying them comparatively and competitively. Dont interfere with governments strategy.

Soon, Mr Baguma found himself on the defensive for the first time after a disbelieving public questioned the sudden change of heart.

There is a rumour flying over social media that the leaders have been bribed. The leaders have a responsibility to take leadership if you dont take over your membership, then you can take them to a wrong direction, he said.

A section of Art teachers, who have since resumed teaching, said they are working with an extremely low morale.

Speaking on the floor of Parliament this past week, Opposition Chief Whip John Baptist Nambeshe (Manjiya County) said the selective enhancement of salaries has opened a Pandoras box.

Read the original post:
Anatomy of Unatu standoff with government | Monitor - Monitor

A ‘Grey’s Anatomy’ Writer Has Allegedly Swindled Shonda Rhimes in the Style of Shondaland’s ‘Inventing Anna’ – Showbiz Cheat Sheet

Shonda Rhimes is no stranger to tales that contain fact stranger than fiction. One of the writer and producers most recent projects, Inventing Anna, followed the story of a pathological liar. Now, it seems like one of Rhimes own Greys Anatomy writers is guilty of the same thing. So, who is Elisabeth Finch?

Finch started writing for Greys Anatomy after a since-deleted personal essay of hers published by Elle. In the piece, she discussed living and working with chondrosarcoma, a rare and usually fatal form of bone cancer. In her essay, Finch talked about how she continued working against the orders of her doctor.

When I defied Dr. Cryptics orders to take an indefinite leave of absence from work he thought chemo deserved my sole attention he doubted my commitment to getting well, she wrote in her article, according to Vanity Fair. At the time, Finch was working on The Vampire Diaries.

I watched the producers cuts under a fog of Demerol, punched up dialogue about vampire-werewolf hybrids with a shunt in my spine, Finch continued. Yes, I was down 17 pounds, bald, vomiting relentlessly, but I was still living alone. Still stubborn as hell.

The Elle essay caught the eye of a development executive at Shondaland, Rhimes production company. Finch ended up getting hired to work on Greys Anatomy. Since joining the show in 2014, Finch was credited as a producer on 172 episodes, and a writer for 13.

Most notably, Finch was credited as a writer on a 2018 episode of the medical drama, called Anybody Have a Map? In the episode, a patient undergoes an operation to treat her aggressive chondrosarcoma.

The people who worked at Shondaland were extremely supportive of Finch. They granted her time off for her chemotherapy and clinical trials. They also found her story inspirational; Finch was the only person who survived in one of her clinical trials yet she still came to work as often as she could.

After years of working at Shondaland, everyone thought they knew Finchs story. That all changed in 2022 when Rhimes received a mysterious email. The message was from Jennifer Beyer, Finchs estranged wife.

Beyer was writing to tell Rhimes that Finch was lying. Even though no one wanted to believe it, as they looked into Finchs story, things started to fall apart.

Finch first claimed she had been diagnosed with cancer while she was working on The Vampire Diaries. According to Vanity Fair, she would visit her family in New Jersey, bald from alleged chemo treatments and sporting a bandage where the chemo port would be.

However, Beyer claimed Finch still had her eyebrows and eyelashes. Notably, chemo patients typically lose these features while being treated. Also, she didnt have a scar where the port would have been.

According to Beyer, when she became suspicious and confronted Finch, the writer admitted, She had at one time had cancer, but that she got chemo, and recovered.

Her estranged wife also claimed that Finch lied about her brother committing suicide (hes alive), a friend dying in the mass shooting at the Tree of Life synagogue, and receiving a kidney from True Blood star Anna Paquin (the actress has denied this claim).

Since her story has been called into question, Finch has gone on a personal leave of absence from Greys Anatomy. Theres no word yet on when, or if, shell come back, or what kind of consequences she might face.

In a statement about her leave, Finch said, according to Deadline, I will always remain one of Greys Anatomys biggest fans. I loved the show from day one and had the honor to write for it since season 11. The proudest moment of my career was watching survivors of rape receive the episode Silent All These Years.

Greys Anatomy is one big-hearted, brilliant family, she continued. As hard as it is to take some time away right now, I know it is more important that I focus on my own family and my health. Im immensely grateful to Disney, ABC, and Shondaland for allowing me to do so and for supporting me through this very difficult time.

Finchs story of sickness, death, and organ donation has not been confirmed or denied. But fans cant help but point out the crazy similarity between her story and Rhimes own Inventing Anna series.

RELATED: Greys Anatomy: Sandra Oh Says Fame Literally Made Her Sick

Visit link:
A 'Grey's Anatomy' Writer Has Allegedly Swindled Shonda Rhimes in the Style of Shondaland's 'Inventing Anna' - Showbiz Cheat Sheet

Mobile X-ray Leaps into the Future with New Innovations from Konica Minolta Healthcare – Health Imaging

WAYNE, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc. announced today that the companys revolutionary Dynamic Digital Radiography (DDR) technology, enabling the visualization of anatomyin motion, will be available on the mKDR Xpress Mobile X-ray System.1The mobile system will also be compatible with the newest technology in wireless flat panel X-ray detectors, the AeroDRGlassless High Definition Detector. Both solutions enable clinicians to realize greater potential with X-ray, the most widely available diagnostic imaging modality and often the first imaging test a patient receives. These new advancements in X-ray technology are being introduced at the Association for Medical Imaging Management (AHRA) 2022 Annual Meeting in Phoenix at Konica Minoltas booth.

DDR is the next evolution in X-ray, enhancing diagnosis and management of pulmonary diseases and orthopedic conditions. DDR enables clinicians to visualize the dynamic interaction of anatomical structures, such as tissue and bone, with physiological changes over time. DDR is not fluoroscopy; it is a series of individual digital images acquired at high speed and low dose. In the same study, clinicians can acquire static and dynamic images. The resulting cine loop delivers up to 40 seconds of anatomy in motion in a diagnostic-quality view with a simple acquisition performed on a conventional DR system. DDR has been adopted by academic and community hospitals, orthopedic and spine clinics, and pulmonary centers across the US.

Pairing DDR with the high-performance mKDR Xpress enables clinicians to elevate patient care with mobile X-ray at the point of care in a hospital, says Guillermo Sander, PhD, Marketing Director for Digital Radiography, Konica Minolta Healthcare. Whether it is used to visualize anatomy in motion or observe physiological cycles, DDR adds significant clinical value with an exam that is fast and versatile at a low radiation dose. It is the only technology of its kind available today and in portable imaging, X-ray in motion is only possible on the mKDR Xpress.

The mKDR Xpress delivers exceptional imaging performance in a small footprint at the bedside or in the ER, OR, CCU or ICU. With a slim design and collapsible column to facilitate its use in tight spaces, the mKDR Xpress can be more easily moved wherever its needed. On-board charging for two detectors and front and back storage for detectors and accessories help technologists meet the most demanding mobile X-ray imaging needs. An industry-unique, tube-mounted graphical user interface and image preview function help ensure clear images are visible quickly, improving efficiency when time matters.

Lightweight and durable with enhanced sensitivity and resolution, the AeroDR Glassless Flat Panel Detector is the ideal wireless panel for mobile X-ray, as well as other applications. A glassless substrate replaces the glass-based substrate in the design for a detector that weighs 27% less than prior generation AeroDR Flat Panel Detectors only 4.2 lbs. with the built-in power cell. AeroDR Glassless Flat Panel Detectors deliver the same robust imaging and reliability as other models of AeroDR Flat Panel Detectors with an excellent drop impact resistance, an antibacterial carbon enclosure and eight hours of use after a 30-minute charge.

With a high detective quantum efficiency (DQE) and the worlds smallest pixel size of 100m, the AeroDR Glassless Flat Panel Detector delivers the resolution and image sharpness clinicians need to confidently evaluate the patients anatomy, even the finest and smallest structures. Intelligent Grid for grid-less imaging and tube and gauze image enhancement with REALISM make it ideal for use in surgical imaging applications.

Konica Minolta is imagining more possibilities with DR and mobile X-ray to help clinicians meet their most demanding imaging needs, providing solutions that redefine what radiography can do, adds Sander. We envision a world where advanced X-ray capabilities provide the immediacy of information that clinicians need, at a lower cost than other imaging systems, so they can make better decisions, sooner.

1Dynamic Digital Radiography on the mKDR Xpress Mobile X-ray System is pending US FDA 510(k) clearance.

About Konica Minolta Healthcare Americas, Inc.Konica Minolta Healthcare is a world-class provider and market leader in medical diagnostic imaging and healthcare information technology. With over 75 years of endless innovation, Konica Minolta is globally recognized as a leader providing cutting-edge technologies and comprehensive support aimed at providing real solutions to meet customers' needs and helping make better decisions, sooner. Konica Minolta Healthcare Americas, Inc., headquartered in Wayne, NJ, is a unit of Konica Minolta, Inc. (TSE:4902). For more information on Konica Minolta Healthcare Americas, Inc., please visithttps://healthcare.konicaminolta.us

Contact:Mary Beth MassatMassat Media224.578.2388https://healthcare.konicaminolta.us

A photo accompanying this announcement is available athttps://www.globenewswire.com/NewsRoom/AttachmentNg/5da9585c-0b53-4008-b2b6-86d60725bf8b

See the original post:
Mobile X-ray Leaps into the Future with New Innovations from Konica Minolta Healthcare - Health Imaging

Better orthodontic impressions with the putty + wash method – Dental Economics

I have found myself needing to consistently capture an accurate full-arch impression without voids. The easy answer, nowadays, is to use a digital scanner and capture the impression digitally. But many of our colleagues do not have the time and/or the money to invest in such equipment.

Additionally, certain orthodontic products offered on the market require digital impressions from a specific brand of digital scanner. That scanner, and many other scanners, typically would not yield an ROI signficant enough to warrant the initial, and ongoing, investment for many practitioners.

Instead, most of us use some sort of combination of heavy- and light-body vinyl polysiloxane (VPS) to capture impressions. The heavy and light bodies are dispensed out of a cartridge and then placed in one step into the patients mouth. Most of the time this works out well for capturing one, two, or three-plus indirect restorations.

Transforming patients and practices through a seamless digital workflow

Implant impressions: Tips and tricks for better results

But what about when an accurate full-arch model is taken? It is incredibly difficult to capture every detail of an arch in one shot using a one-step VPS impression. Theres a high chance that some portion of a tooth or vestibule will be missed. Certainly, custom trays can help, but those require an extra impression, an extra expense for the practice, and extra time for practitioner and patient. This is hardly ideal in todays private practice climate and expectations of our patients.

My everyday clinical technique to address this is the putty + wash method. I had heard about this method many times previously, but over time I have been able to perfect and utilize it in private practice with repeatable and precise results.

I mostly use the putty + wash method for full-arch impressions required for clear aligner orthodontia. However, its also useful for fabricating flippers, pre-wax-up models, and stents for indirect temporization once a wax-up is back from the lab. Some practitioners have used this as the final impression method for indirect restorations, but I personally have not attempted that technique.

I have been lucky enough to try various companies VPS materials and compared them using the putty + wash method. Along the way, one of my favorites has become Vocos V-Posil line of materials. Not only is this material top-of-the-line, but it has also been one of the most consistent products I have used.

V-Posil does all that it is advertised to do and more: Excellent tear strength and elasticitycheck. Exceptional dimensional stability post-setcheck. Contact angle similar to that of polyether for better hydrophilicity and displacement of fluidscheck. Fast-set time frame for patient comfort and clinical efficiencycheck.

It even has a secondary setting reaction using the oral cavitys and bodys heat to snap-set instead of having to wait for the catalyst-base reaction to finish. What does that mean clinically? A long pre-insertion working time and a faster post-insertion set time.

I encourage everyone to try Vocos V-Posil VPS material. I have found it to be one of the best VPS materials on the market. And for those of you who might not have heard of or dont know how the putty + wash method works, look below for a quick guide.

Setup: The initial setup includes: (1)V-Posil Putty Base & Catalyst, (2) V-Posil X-Light/Light VPS 50 mL cartridge and dispensing gun, (3) appropriate impression trays, (4) alcohol wipes, and (5) straight handpiece carbide burs (figure 1).

Initial putty impressions: In figure 2, you can see the initial V-Posil putty impression for both maxillary and mandibular arches. Note that the V-Posil putty has acted as a pseudo-custom tray due to the viscosity of the material. It also allows you to border-mold for further adaptation.

Anatomy removal: I have found that the most predictable way to achieve a rock-solid result is to trim away any undercuts, embrasure spaces, and occlusal anatomy using straight handpiece carbide burs (figure 3). The idea is to leave just enough occlusal stops to have a dimensionally stable seating during the second step of the putty + wash method. This is especially important in the mandible, where there isnt a palate. Note that one side is trimmed of embrasures, undercuts, and pertinent occlusal anatomy (figure 3).

Alcohol clean: In Figure 4, you can see both arches washed and dried with any major debris removed. The most critical step prior to the wash will be using an alcohol wipe inside the entirety of the impression. Any leftover blood or saliva can affect the adherences of the VPS wash to the putty and cause the practitioner to have to retake the wash impression.

The wash: I have found that dispensing the light-viscosity VPS wash to the height of the gingival margin will yield the best final result without the excess causing distress to the patient. In Figure 5, the V-Posil putty did its job beautifully, and you will notice I did not have to overadd the light-viscosity wash to make up for voids in the vestibule.

The final result: The putty + wash method gives the results we as practitioners need for consistent results. Using a material like Vocos V-Posil makes it even easier. Remember to use steady and heavy force when placing the wash into the patients mouth.

Note: Voco is a financial supporter of DE. All products mentioned in this article are used in the authors normal course of practice.

Editor's note: This article appeared in the July 2022 print edition of Dental Economics magazine. Dentists in North America are eligible for a complimentary print subscription. Sign up here.

View original post here:
Better orthodontic impressions with the putty + wash method - Dental Economics

Key to Hepatitis A Replication Discovered – Technology Networks

The viral replication cycle is crucial for a virus to spread inside the body and cause disease. Focusing on that cycle in the hepatitis A virus (HAV), UNC School of Medicine scientists discovered that replication requires specific interactions between the human protein ZCCHC14 and a group of enzymes called TENT4 poly(A) polymerases. They also found that the oral compound RG7834 stopped replication at a key step, making it impossible for the virus to infect liver cells.

These findings, published in the Proceedings of the National Academy of Sciences, are the first to demonstrate an effective drug treatment against HAV in an animal model of the disease.

Our research demonstrates that targeting this protein complex with an orally delivered, small-molecule therapeutic halts viral replication and reverses liver inflammation in a mouse model of hepatitis A, providing proof-of-principle for antiviral therapy and the means to stop the spread of hepatitis A in outbreak settings, said senior author Stanley M. Lemon, MD, professor in the UNC Department of Medicine and UNC Department of Microbiology & Immunology, and member of the UNC Institute for Global Health and Infectious Diseases.

Lemon, who in the 1970s and 80s was part of a Walter Reed Army Medical Center research team that developed the first inactivated HAV vaccine administered to humans, said research on HAV tapered off after the vaccine became widely available in the mid-1990s. Cases plummeted in the 2000s as vaccination rates skyrocketed. Researchers turned their attention to hepatitis B and C viruses, both of which are very different from HAV and cause chronic disease. Its like comparing apples to turnips, Lemon said. The only similarity is that they all cause inflammation of the liver. HAV is not even part of the same virus family as hepatitis B and C viruses.

Hepatitis A outbreaks have been on the rise since 2016, even though the HAV vaccine is very effective. Not everyone gets vaccinated, Lemon pointed out, and HAV can exist for long periods of time in the environment such as on our hands and in food and water resulting in more than 44,000 cases, 27,000 hospitalizations and 400 deaths in the United States since 2016, according to the CDC.

Several outbreaks have occurred over the past several years, including in San Diego in 2017 driven largely by homelessness and illicit drug use, causing severe illness in about 600 people and killing 20. In 2022, there was a small outbreak linked to organic strawberries in multiple states, leading to about a dozen hospitalizations. Another outbreak in 2019 was linked to fresh blackberries. Globally, tens of millions of HAV infections occur each year. Symptoms include fever, abdominal pain, jaundice, nausea, and loss of appetite and sense of taste. Once sick, there is no treatment.

In 2013, Lemon and colleagues discovered that the hepatitis A virus changes dramatically inside the human liver. The virus hijacks bits of cell membrane as it leaves liver cells, cloaking itself from antibodies that would have otherwise quarantined the virus before it spread widely through the blood stream. This work was published in Nature and provided insight into how much researchers had yet to learn about this virus that was discovered 50 years ago and has likely caused disease dating back to ancient times.

A few years ago, researchers found that hepatitis B virus required TENT4A/B for its replication. Meanwhile, Lemons lab led experiments to search for human proteins that HAV needs in order to replicate, and they found ZCCHC14 a particular protein that interacts with zinc and binds to RNA.

This was the tipping point for this current study, Lemon said. We found ZCCHC14 binds very specifically to a certain part of HAVs RNA, the molecule that contains the viruss genetic information. And as a result of that binding, the virus is able to recruit TENT4 from the human cell.

In normal human biology, TENT4 is part of an RNA-modification process during cell growth. Essentially, HAV hijacks TENT4 and uses it to replicate its own genome.

This work suggested that stopping TENT4 recruitment could stop viral replication and limit disease. Lemons lab then tested the compound RG7834, which had previously been shown to actively block Hepatitis B virus by targeting TENT4. In the PNAS paper, the researchers detailed the precise effects of oral RG7834 on HAV in liver and feces and how the viruss ability to cause liver injury is dramatically diminished in mice that had been genetically modified to develop HAV infection and disease. The research suggests the compound was safe at the dose used in this research and the acute timeframe of the study.

This compound is a long way from human use, Lemon said, But it points the path to an effective way to treat a disease for which we have no treatment at all.

The pharmaceutical company Hoffmann-La Roche developed RG7834 for use against chronic hepatitis B infections and tested it in humans in a phase 1 trial, but animal studies suggested it may be too toxic for use over long periods of time.

The treatment for Hepatitis A would be short term, Lemon said, and, more importantly, our group and others are working on compounds that would hit the same target without toxic effects.

Reference: Lemon SM et al.The ZCCHC14/TENT4 complex is required for hepatitis A virus RNA synthesis. PNAS; 2022. doi:10.1073/pnas.2204511119

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Original post:
Key to Hepatitis A Replication Discovered - Technology Networks

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 – Yahoo Finance

SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ --Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody.

The Phase I study is a multi-stage, double-blind, randomized, placebo-controlled, dose-escalation study in healthy volunteers, and a dose-escalation and parallel design, multiple-dose study in adult patients with moderate to severe atopic dermatitis. The study will be used to evaluate the safety, tolerability and efficacy of IMG-007 in patients with atopic dermatitis. Additional details will be found at clinicaltrials.gov, using identifier NCT05353972.

"Dosing the first participant is an important milestone for the IMG-007 program," said Dr Jonathan Wang, Chairman and Chief Executive Officer of Inmagene. "We hope the data will help us demonstrate that IMG-007 is one of the strongest OX40 antagonist drug candidates worldwide."

Dr Jean-Louis Saillot, Chief Development Officer of Inmagene, said, "IMG-007 blocks the OX40 activity and has demonstrated high potency in preclinical studies, indicating a best-in-class potential. We welcome the start of the IMG-007 clinical program with the hope of developing an innovative, safe and effective treatment option for patients with atopic dermatitis and other immunological diseases."

Dr Weiguo Su, Chief Executive Officer and Chief Scientific Officer of HUTCHMED, said: "This is an exciting step towards taking our novel drug candidates into immunological diseases, where Inmagene has significant expertise, as we work to maximize the impact of our drug discovery engine."

About IMG-007

IMG-007 is a novel antagonistic monoclonal antibody targeting the OX40 receptor. It was originally discovered by HUTCHMED, with Inmagene assuming development responsibility at the candidate stage. Inmagene has an exclusive option to in-license IMG-007's global rights.

Story continues

About OX-40 and Atopic Dermatitis

OX40 is a costimulatory receptor member of the tumor necrosis factor receptor (TNFR) superfamily expressed predominantly on activated T cells. The ligation of OX40 by its ligand OX40L leads to enhanced T cell survival, proliferation, and effector functions. Preclinical research results show that IMG-007 can bind to human OX40 receptor with high affinity, thereby inhibit the binding of OX40 to OX40L, reducing OX40L-dependent downstream signaling and cytokine release by OX40+ T cells. By selectively shutting down OX40+ T cell function, IMG-007 may provide a treatment option for pathological OX40+ T cell-mediated immune diseases, such as atopic dermatitis.

Atopic dermatitis is a chronic inflammatory skin condition that is estimated to affect 8-19% of children and 2-5% of adults in US, Europe, and East Asia.[1],[2],[3]

About Inmagene

Inmagene is a global clinical-stage biotechnology company focused on developing novel therapeutics for immunology-related diseases. The company is building a robust pipeline of nearly twenty drug development programs.

Inmagene's most advanced drug candidate is IMG-020 (izokibep), which has successfully met the endpoints in global phase II studies for both psoriasis and psoriatic arthritis ("PsA"). It has received the IND approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for phase III studies in plaque psoriasis. Inmagene is working with its partners to conduct global phase II studies for multiple autoimmune diseases, including PsA, ankylosing spondylitis (AS) and uveitis. In addition, IMG-004 and IMG-007, both of which with global rights, are in global phase I studies.

Believing in "Borderless Innovation", the Inmagene team strives to integrate efficient resources worldwide to develop novel therapeutics for global patients. Based on its proprietary QuadraTek drug discovery platform, Inmagene is operating 12 "Smart Innovation" programs to create and develop drug candidates with global rights. Inmagene also in-licenses drug candidates and, together with its partners, carries out global development activities, including global multi-center clinical trials. Inmagene has formed strategic partnerships with multiple partners, such as HUTCHMED and Affibody AB, to develop highly innovative drug candidates. For more information, please visit: http://www.inmagenebio.com

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,900 personnel across all its companies, at the center of which is a team of over 1,800 in oncology/immunology. Since inception it has advanced 13 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: http://www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Inmagene's and/or HUTCHMED's current expectations regarding future events, including expectations regarding the therapeutic potential of IMG-007 for the treatment of patients with atopic dermatitis and other immunological diseases, the further clinical development of IMG-007, expectations as to whether clinical studies of IMG-007 would meet their primary or secondary endpoints, and expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study's inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of IMG-007 to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of IMG-007 for a targeted indication; the sufficiency of funding; and the impact of the COVID-19 pandemic on general economic, regulatory and political conditions. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of various risks applicable to HUTCHMED, see HUTCHMED's filings with the U.S. Securities and Exchange Commission, on AIM and with The Stock Exchange of Hong Kong Limited. Neither Inmagene nor HUTCHMED undertakes to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

[1] Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-428.e2. doi:10.1016/j.anai.2020.12.020

[2] Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018;73(6):1284-1293. doi:10.1111/all.13401

[3] Stnder S. Atopic Dermatitis. N Engl J Med. 2021;384(12):1136-1143. doi:10.1056/NEJMra2023911

Cision

View original content:https://www.prnewswire.com/news-releases/inmagene-and-hutchmed-announce-first-participants-in-global-phase-i-trial-of-img-007-301581096.html

SOURCE Inmagene Biopharmaceuticals

See more here:
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 - Yahoo Finance

All-in-one vaccine will tackle future coronavirus threats – Innovation Origins

As of July 2022, uncertainty persists as waves of SARS-CoV-2 continue to emerge. Over time, new virus variants arise and threaten to reduce the impact of existing vaccine efforts. There is a clear need for strategies to both tackle emerging variants, and to protect populations against potential future threats to human health such as related bat viruses, writes the University of Oxford in a press release.

A new consortium aims to address these issues by establishing the first-in-human clinical proof of concept for a new vaccine design. The vaccine will target both SARS-CoV-2 and a number of related bat viruses which have the potential to spread to humans. It builds on technologies developed by the Molecular Immunology Group at the University of Oxford and by the Bjorkman Group based at Caltech led by Professor Alain Townsend at the MRC Human Immunology Unit and by Professor Pamela Bjorkman respectively.

In contrast to many existing vaccine designs that use mRNA or a viral vector to present sections of the spike protein of a single type of virus to the immune system, this new vaccine will use protein nanoparticles containing a protein glue to attach related antigenic sections of the spike proteins from eight different viruses. By incorporating a mosaic-8 vaccine design created at Caltech these nanoparticles would favour immune responses to the shared parts of each of the different types of coronaviruses within a single vaccine.

Evidence published today in Science by the researchers demonstrates that this vaccine technology not only elicits protective immune responses against SARS-like virusesbutalso against some coronaviruses not presented in the trial vaccine. This suggests that the technology could provide protection against future novel SARS-CoV-2 variants and as-yet-undiscovered coronaviruses with the potential to spill over from animal populations.

Using Artificial Intelligence to monitor and manage COVID-19

A study by researchers at the Universitat Politcnica de Valncia (UPV), part of BDSLab-ITACA group and the Institute of Pure and Applied Mathematics (IUMPA), has become an international benchmark for the reliable use of artificial intelligence in monitoring and managing COVID-19.

Alain Townsend, Oxford Lead of the consortium, Professor of Molecular Immunology at the MRC Weatherall Institute of Molecular Medicine, University of Oxford, said: The evolution of this consortium is an example of collaborative science at its best. We had been deeply impressed by the power of the glue for sticking proteins together developed by Mark Howarth (Biochemistry Oxford),and derived from his beautiful basic science investigations of the Streptococcus pyogenes bacterium.

Throughconnections made byIan Wilkinson (Absolute Antibody), we joined with colleagues at Ingenza and CPI who succeeded in making a fully functional version of the vaccine produced in microbes, thus reducing the cost of production. We have been collaborating with Prof. Pamela Bjorkman and the Caltech team, who had independently developed the brilliant concept of the mosaic version of the vaccine and are excited to continue working with this world-class consortium.

The consortium aims to commence a Phase 1 trial in 2024, led by the Oxford Vaccine Group.

More here:
All-in-one vaccine will tackle future coronavirus threats - Innovation Origins

Wheres the herd immunity? Our research shows why Covid is still wreaking havoc – The Guardian

We are all so very tired of Covid-19, and there are many other crises to wrestle with. This pandemic has been going on since the beginning of 2020, and a state of hypervigilance can only be maintained for so long. And yet, just live with it looks self-evidently too thin a recipe and, currently, not very workable or successful with the emergence of BA.4 and BA.5 Omicron subvariants.

According to the latest numbers, released today, the UK added more than half a million new Covid infections in the past week, and the estimated number of people with Covid in total was somewhere between 3% and 4% of the population.

Many have been rather unwell and off work or school, with the associated disruptions to education, healthcare and other vital services. These infections will also inevitably add to the toll of long Covid cases. According to ONS data, the supposedly mild waves of Omicron during 2022 have brought more than 619,000 new long Covid cases into the clinical caseload, promising an enduring and miserable legacy from this latest phase.

Rather than a wall of immunity arising from vaccinations and previous infections, we are seeing wave after wave of new cases and a rapidly growing burden of long-term disease. Whats going on? The latest scientific research has some answers.

During May and June two new variants, BA.4 and BA.5, progressively displaced the previous Omicron subvariant, BA.2. They are even more transmissible and more immune-evasive. Last week a group of collaborators, including me and a professor of immunology and respiratory medicine, Rosemary Boyton, published a paper in Science, looking comprehensively at immunity to the Omicron family, both in triple-vaccinated people and also in those who then suffered breakthrough infections during the Omicron wave. This lets us examine whether Omicron was, as some hoped, a benign natural booster of our Covid immunity. It turns out that isnt the case.

We considered many facets of immunity, including the antibodies most implicated in protection (neutralising antibodies), as well as protective immune memory in white blood cells. The results tell us it is unsurprising that breakthrough infections were so common. Most people even when triple-vaccinated had 20 times less neutralising antibody response against Omicron than against the initial Wuhan strain. Importantly, Omicron infection was a poor booster of immunity to further Omicron infections. It is a kind of stealth virus that gets in under the radar without doing too much to alert immune defences. Even having had Omicron, were not well protected from further infections.

Also, to be added to the now complex mix is immune imprinting. This is the finding that our immune response to Covid is shaped very differently, depending on our prior exposures infection in one wave relative to another, plus vaccination. In our study, those whod been infected in the first wave and then again with Omicron had particularly poor T-cell responses and no boosting of antibodies. That is, some combinations of exposures may leave us poorly protected relative to others.

Contrary to the myth that we are sliding into a comfortable evolutionary relationship with a common-cold-like, friendly virus, this is more like being trapped on a rollercoaster in a horror film. Theres nothing cold-like or friendly about a large part of the workforce needing significant absences from work, feeling awful and sometimes getting reinfected over and over again, just weeks apart. And thats before the risk of long Covid. While we now know that the risk of long Covid is somewhat reduced in those who become infected after vaccination, and also less in those from the Omicron than the Delta wave, the absolute numbers are nevertheless worrying.

Not having got long Covid after a prior infection in the earlier waves offers no guarantee against getting it this time. As an immunologist struggling to decode long Covid mechanisms and potential treatments, it is both perplexing and not a little devastating that this mysterious, lingering disease finds a way to continue wreaking havoc in the face of a largely vaccinated population and a supposedly milder variant. Theres an ever-growing cohort of rather desperate long-haulers, many now affected for well over two years, starting to have difficult legal conversations about medical early retirement and personal independence payment support. They need answers, treatments and to know that we take the situation sufficiently seriously to stop creating more cases.

The first generation of vaccines served brilliantly to dig us out of the hole of the first year, but the arms race of boosters versus new variants is no longer going well for us. The UK has only offered a limited group fourth doses, and even then, uptake looks poor. Even if we had good vaccination coverage, we have entered a period of diminishing returns. A study reported in the BMJ last week showed us that the protection gained from a fourth booster dose likely wanes even faster than previous boosters. This leaves us between a rock and a hard place: continue to offer suboptimal boosters to a population who seem to have lost faith or interest in taking them up, or do nothing and cross our fingers that residual immunity might somehow keep a lid on hospitalisations (as happened in South Africa and Portugal).

There is massive activity to develop second-generation vaccine options that might do better including variant-specific vaccines or pan-coronavirus vaccines. While there are promising lab studies on these, we lack the evidence comparable to the huge, first-generation trials that inspired confidence during 2020. Conducting trials has become much harder as we struggle to keep pace with the emergence of new subvariants.

From where I stand, living with the virus is proving hard for many. This fight is far from over, and learning how to pull this off is an active process requiring considerable effort, intervention and ingenuity.

Original post:
Wheres the herd immunity? Our research shows why Covid is still wreaking havoc - The Guardian

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Trnsn – Yahoo Finance

Global Commercial Executive Brings 20 Years of Sales and Marketing Expertise Jan Van den Bossche Steps Down from Board After Six Year Tenure

NEW YORK, July 6, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the appointment of Maria Trnsn, an industry executive with 20 years of global commercial experience in U.S. and ex-U.S. markets, to its Board of Directors, effective July 5, 2022. The company also announced that Jan Van den Bossche has stepped down from the Board, effective July 5, 2022.

"Maria is a seasoned commercial executive, with 20 years of experience in sales and marketing as well as several operational and strategic leadership roles in the U.S., EMEA, and other global territories," stated Duane Nash, M.D., J.D., MBA., Chairman of the Board of Directors of Immunic. "Her expertise in scaling and optimizing commercial organizations to drive performance will be of tremendous value to the Board, as we continue to advance our three development programs, most notably, the phase 3 ENSURE program of lead asset, vidofludimus calcium, in patients with relapsing multiple sclerosis. I look forward to working with Maria and to leveraging her extensive knowledge and relationships."

"I would also like to take this opportunity to thank Jan for his dedication to Immunic and his invaluable input as a member of the Board of Directors over the last several years. We are very grateful for his contributions and offer him our best wishes in all future endeavors."

Ms. Trnsn has served since July 2021 as Chief Commercial Officer at Passage Bio, where she is responsible for leading and building out the company's commercial organization and strategy, including determining product positioning and paths to commercialization. From 2019 to 2021, Ms. Trnsn served as Senior Vice President and General Manager of Sarepta Therapeutics' U.S. Commercial organization, including market access, trade & distribution, reimbursement, sales, patient services and marketing. From 2017 to 2019, she was Vice President, Global Therapeutic Area Head of rare neurological, metabolic and endocrine diseases at Sanofi Genzyme, where she managed a $1.6 B portfolio with five marketed and three pipeline products, and was commercial lead on multiple alliances. From 2011 to 2017, Ms. Trnsn held advancing commercialization roles in the endocrine and rare diseases groups at Shire, rising to the role of Vice President, Head of Endocrine Rare Disease Sales, U.S. Commercial. Earlier in her career, she gained experience in global marketing and as a Product Specialist at Merck KGaA and Eli Lilly, respectively.

Story continues

Ms. Trnsn earned a Master of Science (MSc) in International Business Administration from Lund University, Sweden.

About Immunic, Inc.Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, vidofludimus calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR/RORt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barr syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit: http://www.imux.com.

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, expected timing and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's three development programs and the targeted diseases; the potential for Immunic's development programs to safely and effectively target diseases; the nature, strategy and focus of the company and further updates with respect thereto; expectations regarding the capitalization, resources and ownership structure of the company; and the executive and board structure of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on February 24, 2022, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

Immunic, Inc.Jessica BreuHead of Investor Relations and Communications+49 89 2080 477 09jessica.breu@imux.com

US IR ContactRx Communications GroupPaula Schwartz+1 917 322 2216immunic@rxir.com

US Media ContactKOGS CommunicationEdna Kaplan+1 617 974 8659kaplan@kogspr.com

Immunic, Inc. Logo (PRNewsfoto/Immunic, Inc.)

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-inc-strengthens-its-board-of-directors-with-the-appointment-of-maria-tornsen-301581253.html

SOURCE Immunic, Inc.

Read more from the original source:
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Trnsn - Yahoo Finance